Retatrutide is an investigational GLP-1, GIP and glucagon receptor agonist designed to reduce hunger, increase fullness and affect glucose and energy use.
What Retatrutide does and why that matters
Retatrutide activates three hormone receptors. Its GIP and GLP-1 actions are intended to reduce hunger, increase fullness and improve blood-sugar control. Its glucagon action may add an effect on energy use and liver metabolism. In practical terms, it is being studied to help people eat less and lose weight, but it remains an investigational drug rather than an approved treatment. [1,2]
Function evidence: Three hormone targets with human weight-loss trial evidence
What participants experienced in trials
The practical aim is familiar: feel less hungry, become satisfied with less food and lose enough weight to improve health. Lilly's May 2026 topline release reported substantial average weight loss in the 12 mg arm of TRIUMPH-1 at 80 weeks. That is a real late-stage human signal, not an animal-only claim. It is still sponsor-reported topline information rather than a full peer-reviewed report, so details about adherence, missing data, subgroup responses and uncommon harms remain important. Retatrutide also remains investigational and cannot lawfully be compounded under federal law. [1,2,3]
What supports this description: Sponsor-reported phase 3 topline result; full peer review pending
Retatrutide Dosing status
Dose: No consumer dose is established or recommended here. | Frequency: No routine treatment schedule established. | Cycle: No validated consumer cycle. | Route: No routine patient route established.
Preparation: No patient reconstitution recipe. Trial preparation is not a recommendation..
Retatrutide is an investigational drug that acts at the GIP, GLP-1 and glucagon receptors. Lilly announced topline Phase 3 results from TRIUMPH-1 in May 2026. At 80 weeks, average weight loss in the 12 mg arm was 28.3% under the efficacy estimand and 25.0% under the treatment-regimen estimand, compared with 2.2% and 3.9% for placebo. The full results have not yet appeared in a peer-reviewed publication. [1,2]
Retatrutide Effects
Phase 3 obesity result. In the sponsor release, the 12 mg group averaged 28.3% weight loss under the efficacy estimand and 25.0% under the treatment-regimen estimand at 80 weeks; placebo averaged 2.2% and 3.9%, respectively. [1]
Evidence status. TRIUMPH-1 is completed in the registry, but the registry does not replace a peer-reviewed report with full methods and analyses. [1,2]
Retatrutide Side Effects
Adverse events in sponsor topline data. At 12 mg, the sponsor reported nausea in 42.4%, diarrhea in 32.0%, constipation in 26.1%, vomiting in 25.3%, and discontinuation for adverse events in 11.3%. These figures await full peer-reviewed reporting. [1]
Illegal compounding and unapproved products. FDA says retatrutide cannot be used in compounding under federal law. Lilly states it is legally available only to clinical-trial participants. Products sold as “research” or “compounded” retatrutide are not approved clinical products. [1,3]
Frequently Asked Questions About Retatrutide
Is retatrutide approved or available by prescription?
No. It remains investigational. Lilly says it is legally available only to clinical-trial participants, and FDA says it cannot be used in compounding under federal law. [1,3]
Do the 1–12 mg trial doses create a consumer titration plan?
No. Doses in a controlled protocol describe the experiment; they are not a recommendation or a recipe for an unapproved product. [1,2]
Evidence
Phase 3 sponsor topline; investigational and not FDA-approved. Retatrutide is an investigational drug that acts at the GIP, GLP-1 and glucagon receptors. Lilly announced topline Phase 3 results from TRIUMPH-1 in May 2026. At 80 weeks, average weight loss in the 12 mg arm was 28.3% under the efficacy estimand and 25.0% under the treatment-regimen estimand, compared with 2.2% and 3.9% for placebo. The full results have not yet appeared in a peer-reviewed publication. [1,2]
Approval status: Not FDA-approved. FDA says retatrutide cannot be compounded under federal law. [1,2,3]
References
Eli Lilly and Company Lilly’s triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial , 2026. Source
ClinicalTrials.gov TRIUMPH-1: A Study of Retatrutide in Participants With Obesity or Overweight (NCT05929066) , 2026. Source
U.S. Food and Drug Administration FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss , 2026. Source
Storage
Educational evidence summary. Approval applies only to the named product and indication; compounded, investigational, and research-market products are different categories.
◇An FDA-approved label or a patient-specific prescription from a licensed pharmacy
◇The active ingredient, strength, dosage form, concentration, lot, and dispensing instructions
◇Identity or purity tests only support the tests performed; they do not prove sterility, endotoxin safety, dose accuracy, stability, or clinical suitability
◇A “research use only” vial is not a patient medicine
